MarketCap
Facebook
X
Telegram
Edesa Biotech Financial Ratios 2025-2011 | EDSA
Brief overview of Edesa Biotech's financial ratios
The comparison uses the five latest available annual observations between 2016 and 2020.
The valuation comparison uses P/S 158.11x (median 158.11x), P/B 0.83x (median 2.03x). The combined multiple level is about 29.5% below the company's historical norm, suggesting more cautious expectations.
Returns on assets and capital are represented by ROE -57.7%, ROA -53.1%, ROCE -63.5%. Negative returns point to losses or poor capital efficiency. Valuation multiples are less informative in this setting.
Current PEG is 0.24x; the market pays comparatively little per unit of expected growth.
The cash return period is stable at 105.4 days initially and 97.1 days at the end.
Overall picture
Edesa Biotech's discount may reflect genuine profitability issues rather than market inefficiency alone.
Annual Financial Ratios Edesa Biotech
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.6 | -1.0 | -1.7 | -0.1 | -3.0 | -8.2 | -10.0 | -3.5 | -98.3 | -157.8 | -935.7 | -10.7 | -4.7 | -2.9 | -2.1 |
P/S |
- | - | - | - | - | 158.1 | 67.9 | 83.7 | 2165.9 | 623.8 | 3506.3 | 242.5 | 129.6 | 52.0 | 21.3 |
EPS |
-1.3 | -1.9 | -2.9 | - | - | -0.7 | - | -0.5 | -3.4 | -0.6 | -0.4 | -1.1 | -2.8 | -0.1 | - |
EV (Enterprise Value) |
497 K | 6.91 M | 10.8 M | -2.67 M | 33.6 M | 48.9 M | 23.3 M | 14.9 M | 490 M | 787 M | 2.66 B | 88.2 M | 74.5 M | 14.6 M | 15 M |
EBITDA per Share |
-1.37 | -2.14 | -3.16 | -7.67 | -1.77 | -0.737 | -0.561 | -1.7 | -0.493 | -0.539 | -0.525 | -30.8 | -28.9 | -61.5 | -77.8 |
EV/EBITDA |
-0.1 | -1.0 | -1.2 | 0.1 | -1.3 | -7.1 | -8.1 | -2.8 | -97.1 | -165.1 | -635.6 | -13.8 | -17.7 | -2.2 | -1.5 |
PEG |
-0.02 | -0.01 | -0.02 | -0.0 | -0.04 | 0.24 | -0.11 | -0.07 | -7.17 | 2.66 | -13.86 | -0.17 | 0.03 | -0.08 | 0.01 |
P/B |
0.8 | 3.1 | 2.0 | 0.2 | 3.1 | 7.8 | 5.3 | 1.6 | 66.8 | 64.4 | 332.3 | 11.7 | -22.5 | 17.5 | 3.2 |
P/CF |
-1.5 | -1.2 | -2.2 | -0.2 | -2.9 | -10.4 | -5.7 | -3.5 | -98.8 | -161.6 | -567.6 | -19.8 | -24.1 | -3.7 | -5.1 |
ROE % |
-57.71 | -311.44 | -118.81 | -186.86 | -102.18 | -95.97 | -52.83 | -44.65 | -67.99 | -40.82 | -35.51 | -109.60 | 473.86 | -610.22 | -154.33 |
ROA % |
-53.11 | -161.77 | -94.20 | -151.60 | -91.49 | -59.13 | -48.56 | -42.78 | -65.16 | -38.85 | -27.37 | -58.31 | -174.86 | -336.60 | -149.16 |
ROCE % |
-63.54 | -354.07 | -130.84 | -195.62 | -181.35 | -69.33 | -53.88 | -44.99 | -70.61 | -39.86 | -54.20 | -43.81 | -79.89 | -664.40 | -155.53 |
Current Ratio |
- | 2.1 | 4.8 | 5.3 | 9.6 | 5.3 | 12.2 | 21.6 | 21.1 | 19.4 | 4.1 | 9.9 | 2.1 | 1.9 | 26.5 |
DSO |
- | - | - | - | - | 97.1 | 192.9 | 71.1 | 2.1 | 24.6 | 75.8 | 55.5 | 118.9 | 21.6 | 20.4 |
DIO |
- | - | - | - | - | - | - | 183.8 | 46.5 | 80.7 | 242.1 | - | - | - | - |
Operating Cycle |
- | - | - | - | - | 97.1 | 192.9 | 254.9 | 48.6 | 105.4 | 317.9 | 55.5 | 118.9 | 21.6 | 20.4 |
Cash Conversion Cycle |
- | - | - | - | - | 97.1 | 192.9 | 254.9 | 48.6 | 105.4 | 317.9 | 55.5 | 118.9 | 21.6 | 20.4 |
All numbers in USD currency
Quarterly Financial Ratios Edesa Biotech
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.25 | -0.49 | -0.28 | -0.28 | - | -0.25 | -0.3 | -0.48 | - | -0.52 | -0.58 | -0.54 | - | -0.68 | - | - | - | - | - | -0.33 | - | -0.36 | -0.19 | -0.26 | -0.52 | -0.2 | -0.26 | -0.15 | -0.61 | -0.3 | -0.15 | -0.11 | - | -0.13 | -0.26 | -0.93 | -2.63 | -0.84 | -0.13 | -0.15 | -0.44 | -0.14 | -0.15 | -0.19 | -0.16 | 0.06 | -0.01 | -0.02 | -0.05 | 0.04 | 0.01 | -0.08 | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.27 | -0.5 | -0.29 | -0.29 | - | -0.27 | -0.3 | -0.55 | - | -0.59 | -0.69 | -0.58 | - | -0.69 | -0.12 | -0.12 | -0.93 | -0.37 | -0.29 | -0.38 | -1.36 | -0.45 | -0.82 | -0.25 | -0.52 | -0.2 | -0.25 | -0.15 | -0.63 | -0.31 | -0.15 | -0.13 | - | -0.13 | -0.26 | -0.89 | -2.57 | -0.83 | -0.13 | -0.14 | -0.41 | -0.13 | -0.14 | -0.15 | 0.02 | 0.01 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-161.89 | -85.96 | -54.83 | -110.16 | -94.05 | -152.23 | -182.90 | -201.38 | -129.94 | -155.23 | -122.98 | -102.66 | -73.95 | -230.85 | -254.45 | -255.36 | -274.14 | -191.19 | -172.42 | -167.00 | -158.94 | -150.58 | -142.86 | -154.89 | -147.29 | -123.31 | -131.48 | -123.88 | -109.38 | -80.57 | -64.20 | -66.37 | -55.02 | -106.51 | -110.19 | -119.28 | -104.93 | -83.36 | -76.57 | -65.36 | -68.61 | -54.99 | -39.50 | -47.80 | -45.42 | -63.54 | -36.76 | -29.24 | -34.43 | 32.57 | -12.84 | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-77.55 | -76.44 | -52.04 | -75.60 | -60.32 | -92.23 | -101.85 | -113.25 | -74.41 | -96.28 | -64.37 | -84.37 | -62.94 | -190.23 | -202.15 | -202.67 | -218.15 | -157.07 | -152.28 | -145.38 | -135.54 | -109.74 | -97.95 | -106.96 | -102.83 | -100.68 | -106.90 | -101.53 | -90.77 | -64.63 | -55.38 | -57.49 | -46.75 | -96.10 | -99.79 | -104.55 | -96.26 | -75.39 | -68.81 | -62.15 | -64.93 | -49.02 | -35.33 | -39.54 | -33.80 | -45.53 | -27.01 | -20.38 | -24.30 | 22.99 | -9.06 | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-171.79 | -89.17 | -57.58 | -124.66 | -107.88 | -175.28 | -213.16 | -234.39 | -150.53 | -176.82 | -136.21 | -108.01 | -76.23 | -241.64 | -264.32 | -264.41 | -290.19 | -264.13 | -253.58 | -316.86 | -301.08 | -227.93 | -211.94 | -154.93 | -147.90 | -124.82 | -133.58 | -126.55 | -113.05 | -83.05 | -66.06 | -67.75 | -55.13 | -107.24 | -111.59 | -120.49 | -105.70 | -82.76 | -74.93 | -63.32 | -63.88 | -9.65 | -11.49 | -13.57 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
- | - | - | - | - | - | - | - | - | 2.2 | - | 3.9 | 4.8 | 6.0 | 6.4 | 8.3 | 5.3 | 3.1 | 6.0 | 6.9 | 9.6 | 15.7 | 9.6 | 10.0 | 6.5 | 6.5 | 6.5 | 6.0 | 12.4 | 12.4 | 12.4 | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.4 | 5.8 | 3.6 | 3.2 | 3.4 | 3.4 | 3.4 | - | 1.5 | - | - | - | - | - | - | - | - | - | - |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 72.5 | 81.3 | 138.3 | 39620.9 | 39620.9 | 95.0 | - | - | - | 71.1 | 27.3 | 0.5 | 5.7 | 31.7 | 31.8 | 7.9 | 43.2 | 39.1 | 18.1 | 25.8 | 91.2 | 18.1 | 17.2 | 16.4 | 55.5 | 9.5 | 137.8 | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2946.3 | - | - | 449.7 | 229.9 | 3040.4 | 27.3 | 80.1 | 254.0 | 336.2 | 32.5 | 189.7 | 131.9 | 158.7 | 89.0 | 219.2 | 101.1 | 80.5 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 72.5 | 81.3 | 138.3 | 39620.9 | 39620.9 | 3041.3 | - | - | 449.7 | 301.0 | 3067.7 | 27.8 | 85.9 | 285.6 | 368.0 | 40.3 | 232.9 | 171.0 | 176.7 | 114.8 | 310.4 | 119.2 | 97.7 | 16.4 | 55.5 | 9.5 | 137.8 | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.3 | 72.5 | 81.3 | 138.3 | 39620.9 | 39620.9 | 3041.3 | - | - | 449.7 | 301.0 | 3067.7 | 27.8 | 85.9 | 285.6 | 368.0 | 40.3 | 232.9 | 171.0 | 176.7 | 114.8 | 310.4 | 119.2 | 97.7 | 16.4 | 55.5 | 9.5 | 137.8 | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Edesa Biotech, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Russia
Israel
Britain
Singapore
USA
China
Japan
Canada